We work hard to attract, retain, and support the most outstanding faculty.

Annals of the rheumatic diseases

OP0023 A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING SECUKINUMAB 300 MG AND 150 MG AT WEEK 52 IN PATIENTS WITH ANKYLOSING SPONDYLITIS WHO DID NOT ACHIEVE INACTIVE DISEASE DURING AN INITIAL 16 WEEKS OF OPEN-LABEL TREATMENT WITH SECUKINUMAB 150 MG.

2022

Authors: A. Deodhar, A. Kivitz, M. Magrey, J. A. Walsh, P. J. Mease, M. Greenwald, R. Calheiros, F. Kianifard, C. Elam, K. Nagar, A. Winseck, L. S. Gensler

Annals of the rheumatic diseases

OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY.

2022

Authors: D. Van der Heijde, X. Baraliakos, M. Dougados, M. Brown, D. Poddubnyy, F. Van den Bosch, N. Haroon, H. Xu, T. Tomita, L. S. Gensler, M. Oortgiesen, C. Fleurinck, T. Vaux, A. Marten, A. Deodhar

Annals of the rheumatic diseases

OP0154 COMORBIDITY CLUSTERS IN ANKYLOSING SPONDYLITIS AND THEIR ASSOCIATION WITH DISEASE ACTIVITY AND FUNCTIONAL IMPAIRMENT: DATA FROM THE PSOAS COHORT.

2022

Authors: P. Karmacharya, C. S. Crowson, D. Poudel, J. M. Davis, A. Ogdie, J. Liew, M. Ward, M. Ishimori, M. Weisman, M. Brown, M. Rahbar, M. Hwang, J. D. Reveille, L. S. Gensler

Annals of the rheumatic diseases

OP0017 RECAPTURE RATES WITH IXEKIZUMAB AFTER WITHDRAWAL OF THERAPY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS AT WEEK 104 FROM A RANDOMIZED PLACEBO-CONTROLLED WITHDRAWAL STUDY.

2022

Authors: R. B. M. Landewé, D. Poddubnyy, P. Rahman, R. Bolce, S. Liu Leage, J. Lisse, A. Leung, S. Y. Park, L. S. Gensler

TO REMOVE

Lung Function in Women with and without HIV.

2022

Authors: Wang RJ, Nouraie M, Kunisaki KM, Huang L, Tien PC, Anastos K, Bhandari N, Bhatt SP, Bolivar H, Cribbs SK, Foronjy R, Gange SJ, Lazarous D, Morris A, Drummond MB

TO REMOVE

Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial.

2022

Authors: Metra M, Pagnesi M, Claggett BL, Díaz R, Felker GM, McMurray JJV, Solomon SD, Bonderman D, Fang JC, Fonseca C, Goncalvesova E, Howlett JG, Li J, O'Meara E, Miao ZM, Abbasi SA, Heitner SB, Kupfer S, Malik FI, Teerlink JR

TO REMOVE

COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis.

2022

Authors: Deodhar A, Bhana S, Winthrop K, Gensler LS

TO REMOVE

Towards the patient-centred care of rheumatoid arthritis.

2022

Authors: Izadi Z, Schmajuk G

TO REMOVE

The removal of race from kidney function estimation: Key points for primary providers.

2022

Authors: Aklilu A, Delgado C

"HIV within the House Ball Community and the Promise of Community-based Social Structures for Intervention and Support"

Origins of glycan selectivity in streptococcal Siglec-like adhesins suggest mechanisms of receptor adaptation.

2022

Authors: Bensing BA, Stubbs HE, Agarwal R, Yamakawa I, Luong K, Solakyildirim K, Yu H, Hadadianpour A, Castro MA, Fialkowski KP, Morrison KM, Wawrzak Z, Chen X, Lebrilla CB, Baudry J, Smith JC, Sullam PM, Iverson TM